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ABSTRACT
The study aimed to document the impact of the COVID-19 
pandemic on the health and well-being of individuals with 
past and current eating disorders (ED) in Sweden. We re- 
contacted participants with a known lifetime history of ED 
from two previous Swedish studies. Participants completed an 
online survey about health and functioning at baseline early in 
the pandemic (Wave 1 ca May/June 2020; N= 982) and six 
months later (Wave 2 Dec/Jan 2020/21; N= 646). Three impor-
tant patterns emerged: 1) higher current ED symptoms were 
associated with greater anxiety, worry, and pandemic-related 
ED symptom increase; 2) patterns were fairly stable across time, 
although a concerning percentage (23%) who were symptom- 
free at Wave 1 reported the re-emergence of symptoms at Wave 
2; and 3) only a minority of participants (<50%) with a current ED 
were in treatment, and of those in treatment, many reported 
fewer treatment sessions and decreased quality of care. The 
COVID-19 pandemic appears to pose serious health challenges 
for individuals with an ED, whether currently symptomatic or in 
remission. We encourage health service providers and patient 
advocates to be alert to the needs of individuals with ED and to 
take active measures to ensure access to appropriate evidence- 
based care both during and following the pandemic.
Clinical implications
● Higher eating disorder symptom status was linked to higher pandemic- 
related impact
● Especially salient were higher levels of worry, anxiety, and eating disorder 
symptoms
● A quarter of symptom-free individuals reported re-emergence of symp-
toms at 6 months
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● Only a minority with current eating disorders were in treatment
● Many reported fewer treatment sessions than pre-pandemic and 
decreased care quality
Introduction
Coronavirus disease 2019 (COVID-19), an infectious disease caused by severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared 
a pandemic in March 2020 by the World Health Organization. In response, 
countries across the globe implemented varyingly strict measures to limit the 
spread of the virus, balancing the impact of public health measures on social 
isolation, disruption of daily routines, and economic factors. Besides the direct 
and often prolonged impact of COVID-19 on physical and mental health 
(Butler et al., 2020; Carfì et al., 2020) pandemic-related restrictions have also 
adversely affected mental health in the general population (The Lancet 
Psychiatry, 2020; Xiong et al., 2020), and may worsen the symptoms in 
individuals with pre-existing psychiatric illnesses (Gobbi et al., 2020; Hao 
et al., 2020). We surveyed a large sample of individuals with eating disorders 
(ED) in Sweden at two time points: Wave 1 (May/June 2020) and Wave 2 
(Dec/Jan 2020/2021). This was done to document the impact of the pandemic 
and public health measures taken to limit its transmission to individuals 
with EDs.
Several studies emerged early in the pandemic suggesting the adverse 
impact of the pandemic and mitigation measures on individuals with ED. 
Reports included changes in eating, exercise, and sleep patterns due to 
imposed societal constraints, increased weight and shape concerns, exposure 
to triggering environments (e.g., having to spend more time in close quarters 
with family or roommates), and social support, stability, and predictability 
regarding daily routines and a regular meal structure (Castellini et al., 2020; 
Schlegl et al., 2020; Vuillier et al., 2021), factors that have been suggested as 
important to prevent symptom outbreaks and maintain treatment gains 
(Geller et al., 2017; Lindstedt et al., 2015). Individuals surveyed also reported 
increases in ED symptoms, anxiety, and stress as a result of the pandemic 
(Chan & Chiu, 2021; Termorshuizen et al., 2020). In addition, clinical services 
were disrupted in many countries due to social distancing policies as well as 
quarantine of infected patients and care providers. Access to care was dis-
rupted and initially, virtual care was rated as less satisfactory than typical face- 
to-face treatment (Termorshuizen et al., 2020; Weissman et al., 2020), 
although others suggest virtual treatment can be effective for some patients 
at certain stages of their illness (Shaw et al., 2021; Stewart et al., 2021). 
Evidence of exacerbation of ED symptoms in individuals with an ED during 
the COVID-19 pandemic, including increased restricting, binge eating, and 
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exercise behaviors, was documented in studies from Spain (Fernández-Aranda 
et al., 2020), Australia (Phillipou et al., 2020), Germany (Giel et al., 2021; 
Schlegl et al., 2020), the United States and the Netherlands (Termorshuizen 
et al., 2020). Worsening of ED symptoms was shown to be associated with low 
self-directedness, difficulties in emotion regulation, and intolerance of uncer-
tainty (Baenas et al., 2020; Machado et al., 2020; Scharmer et al., 2020). 
Furthermore, patients with ED may have high-stress vulnerability when lock-
down restrictions are lifted, and they are re-exposed to social life. A study in 
Italy before, during, and after the end of lockdown showed that exacerbation 
of general psychopathology in ED patients seen during lockdown may persist 
during the re-opening period (Monteleone et al., 2021).
Sweden’s pandemic response was different from many other countries, with 
no lockdowns and a focus on slowing rather than stopping the spread of 
disease (Ludvigsson, 2020). Social distancing was recommended in public 
places, as well as working from home and limiting the number of social 
interactions outside one’s household. Visits to nursing homes were banned, 
physical distancing at restaurants, bars, and events was enforced by restricting 
opening hours and the number of customers, while universities and schools 
for older children (>16 years) closed at least temporarily (Ludvigsson, 2020). 
Pre-schools and schools for younger children remained open. ED treatment 
units remained open, only transitioning to telehealth with patients where it 
was deemed appropriate. This less restrictive approach may have resulted in 
fewer, or different, negative effects for individuals with current or past EDs, 
compared to countries with a more restrictive approach. Moreover, Sweden 
has universal health care with free or low-cost, heavily subsidized treatment, 
and limited poverty. Therefore, temporary or permanent work layoffs had 
little impact on people’s ability to engage in treatment or afford food required 
by, e.g.,, their treatment plan.
Aims of the study
Analysis of Sweden-specific data is valuable since the country has had a unique 
response to COVID-19 public health management (Baral et al., 2021; 
Ludvigsson, 2020). Our primary aim was to field an investigation to charac-
terize the experiences of individuals with a current or past ED in Sweden 
during the COVID-19 pandemic using a longitudinal design with assessments 
at baseline early during the pandemic (Wave 1) and after 6 months (Wave 2). 
Pandemic-related restrictions were similar at both time points, but there were 
more people in intensive care units and more people dying from COVID-19 
when Wave 2 data were collected (https://www.folkhalsomyndigheten.se). We 
examined descriptive statistics regarding illness status, ED symptoms, anxiety, 
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treatment availability, and COVID-19-related concerns over time. We also 
investigated baseline variables that were associated with deterioration or 
improvement of illness status over time.
Material and methods
Participants and procedure
We contacted all participants from two previous large-scale ED studies in 
Sweden, the Anorexia Nervosa Genetics Initiative (ANGI) (Thornton et al., 
2018) and the Binge Eating Genetics Initiative-Sweden (BEGIN-SE), who 
had given permission to be recontacted for future research. All participants 
had lifetime history of an ED (and many had current ED; see Results). 
Although all ED presentations were included, the majority of participants 
had anorexia nervosa (AN), given the nature of the parent ANGI study. 
Although all participants had verified diagnoses from the parent studies, 
for the purposes of this study, we used self-reported diagnosis and self- 
reported symptom status. We sent 3,774 emails on May 27th (170 emails 
were undeliverable) and when we froze the first-wave of data collection 
after 6 weeks at which point 982 individuals had responded (27%). 
The second wave, sent only to those who had completed the Wave 1 
survey, was administered between December 22nd 2020 and February 2nd 
2021, and 646 responded (66% of Wave 1). No additional inclusion/exclu-
sion criteria were applied. The study methodology was approved by the 
Swedish Ethical Review Authority (Dnr 2020–04136).
Survey
The survey (see Supplement 1) was modelled after a similar survey used in 
the United States and the Netherlands, developed in collaboration across 
the countries for this project, to rapidly study the impact of the pandemic 
on individuals with EDs (Termorshuizen et al., 2020), that queried physical 
and mental well-being related to COVID-19 in the previous 2 weeks. 
Experienced ED was queried using check boxes and allowing multiple 
diagnoses, and to describe the sample in the present study we used the 
following trumping order: AN, bulimia nervosa, binge-eating disorder, and 
other specified feeding and eating disorder. Participants provided data on 
age, sex, gender identity, diagnostic and treatment status, exposure to 
COVID-19, and current situational circumstances (e.g., quarantined and 
physical distancing). A Likert scale was used to measure the level of concern 
about changes in ED symptoms, frequency of symptoms, and worry related 
to COVID-19. The 7-item version of the Generalised Anxiety Disorder 
Scale (GAD-7) (Spitzer et al., 2006) assessed anxiety, with Cronbach’s 
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alpha of .91 at Wave 1 and .92 at Wave 2. In the interests of clinical 
relevance and ease of communication, we applied the ≥10 cut-off to identify 
unlikely (<10) or likely (≥10) diagnosable generalised anxiety disorder 
(Spitzer et al., 2006) to categorize participants. Free-text items invited 
participants to share additional comments (qualitative analyses not pre-
sented here).
Statistical analysis
We defined three subgroups according to self-reported symptom status, with 
the question “Which of the following statements best describes your experi-
ence?” and response options “I have previously had an ED but am currently 
free of symptoms” (NoSx), “I have previously had an ED and still experience 
some symptoms” (Sx), and “I currently have an ED” (ED). Statistics for each 
wave are based on the symptom grouping reported at that timepoint, whereas 
longitudinal analyses (migration) are based on Wave 1 groupings. Distribution 
at both time points and migration across symptom groups over time are 
shown in Figure 1.
Figure 1. Distribution (n, %) of participants into self-reported symptom-level groups at each 
measurement wave, where NoSx = previous ED but no current symptoms, Sx = previous ED and 
remaining symptoms, and ED = current ED. Circle sizes approximate group size, and migration 
between groups (arrows) is displayed with percentage of starting group moving to another.
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We examined variable distributions in each symptom status group and time 
point. For GAD-7, we used χ2, Cramer’s V (with effect size conventions 
≥.10 = small, ≥.30 = medium, and ≥.50 = large), and standardized residuals 
(where absolute value ≥2 suggests a significant difference) to evaluate omnibus 
and pairwise differences, respectively. For the other survey items, we used χ2 
(see Supplemental Table S1 for χ2and p) and Bonferroni-corrected post hoc 
z-tests. Furthermore, we tested baseline predictors of symptom deterioration 
or improvement using Welch’s t-tests (due to imbalanced design) and Cohen’s 
d effect sizes, by comparing those who changed group over time with baseline 
group peers who did not change. Three contrasts were made possible based on 
statistical power: one symptom status deterioration (NoSx➔NoSx vs. 
NoSx➔Sx) and two comparisons marked by symptom improvement 
(Sx➔Sx vs. Sx➔NoSx and ED➔ED vs. ED➔Sx). That is, we did not combine 
all who improved or deteriorated, respectively, since their differing starting 
points would have risked concealing important effects.
Attrition analyses compared Wave 2 responders with those who responded 
only at Wave 1 to investigate representativeness of the longitudinal subsample, 
on anxiety, worry about symptom increase, and ED symptoms. We selected 
baseline anxiety level (GAD-7, anx_covid, anx_2019; see Supplement) and 
variables that captured ED symptoms and concerns about factors that might 
increase ED symptoms (items ed_exp, concern, and ICB; see Supplement).
Results
Sample characteristics and distribution of ED symptom groups
The sample consisted of 98% biological females, and gender identity distribu-
tion was 97% female, 2% male, and 1% non-binary or other, and mean age was 
32.1 (SD = 8.73; range 18–77). Self-reported previous or current ED diagnosis 
distribution was as follows (participants could mark several response alter-
natives): AN 64%; bulimia nervosa (BN) 37%; binge-eating disorder (BED) 
24%; and other specified feeding and eating disorder (OSFED) 45%; with 12% 
Table 1. COVID-19 exposure and preventive measures; % “Yes” 
responses. See supplement for full questionnaire.
Item Wave 1n (%) Wave 2n (%)
Practicing social distancing 749 (77%) 556 (87%)
Forced isolation 10 (1%) 3 (1%)
Work/study from home 457 (47%) 341 (53%)
Ordered home stay 51 (5%) 37 (6%)
Tested positive for COVID-19 17 (2%) 56 (9%)
Clinical COVID-19 diagnosis 6 (1%) 4 (1%)
Have not had COVID-19 618 (63%) 443 (69%)
Maybe had COVID-19 but not sure 336 (34%) 139 (22%)
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other; and 1% responding “Don’t know/prefer not to answer.” Table 1 shows 
descriptive statistics for COVID-19-related exposure and preventive measures 
at Wave 1 and Wave 2. No significant differences emerged between individuals 
who responded to both waves of data collection and those who responded to 
Wave 1 only on any tested baseline variables.
Figure 1 shows the distribution of the symptom groups NoSx, Sx, and ED at 
each time point. Thirty-four percent had no ED symptoms, 49%/51% (at the 
respective waves) had lingering symptoms, and 16% reported a current active 
ED at each time point. Although the percentages at each time point were very 
similar, migration did occur. A full 23% of the individuals transitioned from 
NoSx at Wave 1 to Sx at Wave 2 (i.e., deterioration); 15% of the individuals 
with Sx at baseline reported NoSx at Wave 2 (i.e., improvement); and 21% of 
the individuals with ED at Wave 1 reported Sx at Wave 2 (i.e., improvement). 
Most individuals, however, remained in the same symptom category across 
time; NoSx = 77%, Sx = 80%, and ED = 77% (see Figure 1).
Table 2. Proportions of each response option regarding self-reported anxiety at each time point, 
by symptom group. See supplement for items.
Item Group
“No change” “Increased” “Decreased”
Anxiety level changed since the end of 2019? Wave 1 Wave 2 Wave 1 Wave 2 Wave 1 Wave 2
NoSx 48% 43% 34% 41% 17% 17%
Sx 35% 29% 51% 54% 14% 17%
ED 33% 20% 58% 67% 10% 14%
NoSx = No ED symptoms; Sx = Some remaining symptoms; ED = Current eating disorder
Figure 2. Proportion of individuals scoring above/below the GAD-7 cut-off (≥10) at each time 
wave, separated by ED status group.
EATING DISORDERS 7
Anxiety and ED symptom variables by symptom status group
Table 2 presents responses to questions regarding whether their anxiety had 
increased since the end of 2019. In all three symptom groups, a higher 
proportion of individuals indicated that this was true at Time 2 than at 
Time 1. In most cases across symptom groups and both waves, participants 
were more likely to attribute their increases in anxiety to COVID-19 (data not 
shown).
GAD-7 was strongly associated with symptom group, and patterns were 
similar across waves , see Figure 2. At Wave 1 and Wave 2, 23% of the NoSx 
group, 49%/51% of the Sx group, and 79%/76% of the ED group scored above 
the cutoff for GAD-7. At each time point, symptom status group was signifi-
cantly associated with GAD-7 group (above/below cutoff); Time 1 χ2 = 139.55, 
p< .001, Cramer’s V= .38, Time 2 χ2 = 84.65, p< .001, V= .36. Within NoSx and 
Table 3. Worry about impact of COVID-19 by symptom group and measurement wave for items 
related to concern about factors leading to increased ED symptoms, ED symptoms themselves, and 
worry about the impact of COVID-19 on others and own health. See supplement for items.







concern_3: Worry that ED symptoms increase 
due to lack of structure
Per cent responding “Somewhat 
concerned” to “Very concerned”
NoSx 10% a 7% a
Sx 33% b 31% b
ED 56% c 61% c
concern_4: Worry that ED symptoms increase 
due to lack of social support
NoSx 3% a 4% a
Sx 20% b 19% b
ED 51% c 48% c
concern_5: Worry that ED symptoms increase 
due to being in a triggering environment
NoSx 9% a 6% a
Sx 32% b 32% b
ED 56% c 53% c
ICB_1: Binge eating bunkered food Per cent responding “Frequently” 
to “Daily or more”
NoSx 1% a 1% a
Sx 8% b 7% b
ED 24% c 23% c
ICB_2: Restricted food intake due to COVID-19- 
related factors
NoSx 5% a 2% a
Sx 14% b 11% b
ED 27% c 24% c
ICB_3: Compensated for food intake food intake 
due to COVID-19-related factors
NoSx 1% a 1% a
Sx 9% b 8% b
ED 26% c 28% c
ICB_4: Worried about not being able to exercise NoSx 17% a 18% a
Sx 36% b 37% b
ED 39% c 46% c
covid_worry_1: Worry about self being infected Per cent responding “Somewhat 
worried” to “Very worried”
NoSx 23% a 39% a
Sx 28% a 38% a
ED 32% a 40% a
covid_worry_2: Worry about others being 
infected
NoSx 79% a 79% a
Sx 78% a 84% a
ED 80% a 86% a
covid_worry_3: Worry about physical health 
being affected
NoSx 28% a 39% a
Sx 37% b 50% b
ED 45% b 54% b
covid_worry_4: Worry about mental health 
being affected
NoSx 42% a 50% a
Sx 59% b 65% b
ED 65% b 73% b
NoSx = No ED symptoms; Sx = Some remaining symptoms; ED = Current eating disorder. 
Proportions with different superscripts within each time point and item are significantly different at Bonferroni- 
corrected p< .05, i.e., symptom status groups differ significantly for those items.
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ED but not Sx at each time point, proportions were also significantly different, 
as attested to by standardized residuals for GAD≥10: T1 NoSx = −5.9, Sx = 1.3, 
ED = 6.3; T2 NoSx = −4.8, Sx = 1.3, ED = 4.7.
Table 3 shows that concern about ED symptom increase due to the pan-
demic 1 was strongly related to symptom status group (see Supplemental Table 
S1 for omnibus χ2 and p-values). Participants in ED were more significantly 
concerned about increased symptoms due to lack of structure and social 
support, and being exposed to triggering environments, than Sx, who in 
turn were more concerned than NoSx. Patterns were similar across waves. 
Table 3 further shows that more participants reported being worried about 
others being infected by COVID-19 than themselves, and increased ED 
symptom level status Sx or ED was associated with higher worry than NoSx. 
Further, participants were descriptively much more worried about their men-
tal health being affected by COVID-19 than their physical health.
A similar pattern emerged with ED symptoms, with significantly higher 
symptoms of binge eating, restrictive eating, and compensatory behaviours the 
more severe the ED symptom status. Concern about not being able to exercise 
was similar in both ED and Sx. Patterns were similar across the waves.
Treatment
Table 4 presents treatment-related results. Most notably, a majority (58% and 
51% at Waves 1 and 2, respectively) reported not being in the current ED 
treatment; 40% had had fewer sessions in the last 2 weeks, and 40% (Wave 1) 
and 46% (Wave 2) experienced their treatment quality as worse or much worse 
than before the pandemic. On the other hand, 27%/28% (representing around 
half of those in treatment; 47% and 55%, respectively) still had face-to-face 
sessions, and 60%/54% reported their treatment being as good or better than 
before the pandemic.







Presence and format of treatment Wave 1 Wave 2 Wave 1 Wave 2 Wave 1 Wave 2 Wave 1 Wave 2
27% 28% 10% 9% 7% 13% 58% 51%
“Fewer sessions” “As many sessions” “More sessions”
Change in session frequency Wave 1 Wave 2 Wave 1 Wave 2 Wave 1 Wave 2
40% 41% 53% 54% 7% 5%
“Better” “As good” “A little worse” “Much worse
Change in ED treatment quality Wave 1 Wave 2 Wave 1 Wave 2 Wave 1 Wave 2 Wave 1 Wave 2
4% 5% 56% 49% 29% 30% 11% 16%
F2F = Face to face; ED = eating disorder. Responses regarding treatment were reported for the ED group only (Wave 
1n= 156, Wave 2n= 102). Responses regarding change in session frequency and treatment quality were asked only 
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Migration between symptom status groups
We explored predictors of change in symptom status between Wave 1 and 
Wave 2 (Table 5): one analysis investigated factors associated with deteriora-
tion and two analyses related to improvement. Those individuals who tran-
sitioned from NoSx to Sx (23% of Wave 1 NoSx in Figure 1; compared to 
those who stayed in NoSx) had significantly higher Wave 1 mean GAD-7 
scores, greater concern about being in a triggering environment, and higher 
worry about not being able to exercise, with medium effect sizes. They also 
had significantly higher concern about lack of structure and social support, 
but with small effect sizes. Individuals who transitioned from Sx at Wave 1 to 
No Sx at Wave 2 (15% of Wave 1 Sx in Figure 1; compared to those who 
stayed in Sx) had lower scores on concerns about lack of structure, social 
support, and being in a triggering environment and lower scores on com-
pensatory behaviours, with small-to-medium effects. Individuals who moved 
from ED at Wave 1 to Sx at Wave 2 (21% of Wave 1 ED in Figure 1; 
compared to those who stayed in ED) had lower baseline GAD-7 scores.
Discussion
The present study investigated the experiences of a Swedish sample with 
a current or past ED early during the COVID-19 pandemic and six months 
later. Using a survey developed in collaboration with researchers in the USA 
and the Netherlands (Termorshuizen et al., 2020), we identified three impor-
tant patterns. First, more severe ED symptom status was associated with 
greater anxiety, worry, and ED symptom increase. Second, the results were 
fairly stable across time, with some exceptions. Third, and quite concerningly, 
only a minority of participants with current ED were in treatment, and of 
those who were in treatment, many reported fewer treatment sessions than 
usual as well as decreased quality of care.
Overall, our results are in line with other findings that the COVID-19 
pandemic appears to pose considerable challenges to ED patients (Branley- 
Bell & Talbot, 2020; Schlegl et al., 2020). Our results closely mirror those 
reported in the methodologically highly similar study from the US and the 
Netherlands (Termorshuizen et al., 2020), suggesting that despite consider-
able differences in the public health measures adopted by these three coun-
tries to limit transmission of COVID-19 (e.g., no lockdowns or closing of 
schools for children <16 years), the impact on individuals with EDs was 
comparable. In particular, our data suggest that people with a previous ED, 
those with enduring symptoms, or a current active disorder, are especially 
vulnerable to anxiety (a common co-morbid symptom in ED: e.g., 
(Fairweather-Schmidt & Wade, 2020; Ulfvebrand et al., 2015)), which may 
worsen due to healthcare disruptions and societal restrictions that have been 
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put in place to control COVID-19. GAD-7 results suggested that full three- 
quarters of individuals with active EDs were also likely to have generalised 
anxiety disorder. However, in the absence of pre-pandemic data, it was not 
possible to determine whether this is higher than would be expected; none-
theless, it reflects the importance of attending to anxiety in the treatment of 
individuals with EDs during the pandemic. Baseline anxiety, weaker social 
support and structure, as well as fears about not being able to exercise were 
all associated with exacerbated ED symptoms. To some extent, symptom 
improvement showed the opposite pattern, as it was associated with lower 
anxiety and higher ratings on social support and structure. Although we 
found relatively few relapses into full ED, a concerning number of indivi-
duals who initially reported being symptom-free reported the re-emergence 
of symptoms as the pandemic progressed.
Clinically, given the pervasive problems with relapse and achieving long- 
term recovery (Keel & Brown, 2010; Khalsa et al., 2017), coupled with the 
social anxiety and interpersonal problems associated with ED (Arcelus et al., 
2013) our results suggest that it may be important for clinicians working with 
EDs during the pandemic to focus on helping patients to address anxiety, 
maintain daily structure and develop social connectedness to aid recovery. 
Even if patients have been transitioned to virtual care, it may be important to 
ensure that they receive adequate social support via families, peers, advocacy 
organizations, or even online forums to maintain accountability and motiva-
tion for recovery. There may also be a need to assess directly individuals’ living 
arrangements. Given limitations on socializing and recommendations for 
physical distancing during the pandemic, individuals may find themselves 
with less freedom and flexibility to extricate themselves from unhelpful or 
even toxic environments that could potentially exacerbate ED symptoms. 
Caregivers should, therefore, remain vigilant for potentially triggering situa-
tions and be prepared to provide practical assistance when necessary.
Although our study provides important knowledge about how individuals 
with ED are coping with the pandemic in Sweden, it has several limitations, 
mainly due to our rapid deployment of the inventory in response to the 
pandemic. First, given our intention to field a survey soon after COVID-19 
was declared a global pandemic, we rapidly translated and adapted a survey 
used in the US and the Netherlands. This precluded steps to ensure sound 
psychometric properties, except for the GAD-7, which is well tested and had 
high internal consistency. Second, we relied on a convenience sample (i.e., 
individuals who had participated in previous studies who agreed to be con-
tacted for future research), which did not reflect the distribution of diagnoses to 
be expected from a community sample and may have biased results. Third, we 
relied on self-report diagnosis and symptom reports to characterize patients, we 
did not collect current weight status, nor did we query race/ethnicity (which is 
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not regarded as ethically acceptable in Sweden barring a clear aim related to 
these factors). Although all participants had formal diagnoses in the past, the 
use of self-reports to establish their current status remains a limitation. Fourth, 
our response rate to the initial survey was low (27%) and we experienced 
attrition between the waves, potentially introducing bias and limiting generali-
sability. Finally, we were underpowered for some analyses; group sizes were low 
for analysing transitions between symptom levels across time.
Nevertheless, we were able to capture fairly early in the pandemic how indivi-
duals in Sweden with ED were being affected, and our results provide valuable 
information for patients and families, clinicians, and advocacy groups about the 
needs of individuals with EDs in Sweden and have the potential to guide care 
strategies and resource planning during this and future pandemics. As anticipated, 
COVID-19 has been particularly challenging for those with existing active mental 
disorders, and even those who are currently symptom-free are challenged to 
remain healthy. As a recent editorial in the Lancet argued, ”those who wish to 
build fairer societies and health systems after the pandemic ends must learn about 
and prioritise the needs of people living with severe mental illness as a matter of 
urgency” (The Lancet Psychiatry, 2020). We encourage ED practitioners and 
advocacy groups to discuss and develop effective resources for patients, families, 
and clinicians for mitigating the effects of COVID-19 during and following the 
pandemic. Given the high percentage of individuals with active EDs who reported 
not being in treatment in our study, along with the concerning number who 
initially reported being symptom-free but who subsequently reported the re- 
emergence of symptoms 6 months later, development of such resources is 
a matter of urgency.
Note
1. Some response options in this item (“concern,” see Supplement 1) are not shown since 
scores were very low as the response options are relatively irrelevant for Swedish 
conditions; these related to concern about not being able to afford food or treatment, 
which is not an issue in Sweden at this point
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